ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.57 +2.58%

+$0.18 today

Market cap
$6.99B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 11.10M

Average 16.40M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$304.94M

FY 2025 · Annual

Investing Cash Flow

-$149.80M

FY 2025 · Annual

Financing Cash Flow

$400.24M

FY 2025 · Annual

+42.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(346.79M)(416.57M)(583.85M)(413.65M)(351.47M)
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
Deferred Income Tax00000
Stock-Based Compensation57.18M40.18M49.16M34.43M36.81M
Change in Working Capital(15.4M)(16M)3.83M(19.42M)(54.33M)
Accounts Receivables000(2.36M)(40.21M)
Inventory000(8.27M)(6.33M)
Accounts Payables00(6.48M)(3.17M)(190K)
Other Working Capital(15.4M)(16M)10.3M(5.62M)(7.6M)
Other Non-Cash Items16.35M36.62M145.44M(10.16M)48.53M
Operating Cash Flow(274.42M)(337.51M)(366.76M)(391.24M)(304.94M)
Capital Expenditures(33.56M)(78.16M)(30.58M)(6.89M)(3.85M)
Acquisitions (Net)000(1M)0
Purchases of Investments00(10.36M)(140.22M)(241.37M)
Sales of Investments0010.47M136.61M95.82M
Other Investing Activities(51.32M)105.46M0(747K)0
Investing Cash Flow(84.89M)27.3M(30.47M)(12.25M)(149.8M)
Debt Repayment338.5M174.07M451.39M96.89M1.72M
Common Stock Issued00110.4M111.36M400.78M
Common Stock Repurchased(4.06M)(616K)000
Dividends Paid00000
Other Financing Activities171.01M60.16M(3.44M)73.38M(2.27M)
Financing Cash Flow505.44M233.61M558.34M281.63M400.24M
Effect of Forex Changes48K284K(292K)(23K)15K
Net Change in Cash146.19M(76.32M)160.82M(121.88M)(54.48M)
Free Cash Flow(307.98M)(415.67M)(397.34M)(398.12M)(308.78M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$351.5M
+ D&A$15.5M
+ Stock-Based Comp$36.8M
+ Deferred Tax$0
- Working Capital-$54.3M
+ Other Non-Cash$48.5M
= Operating Cash Flow-$304.9M
- Capex-$3.8M
= Free Cash Flow-$308.8M

Analysis

FY2025 free cash flow is -$308.8M. FCF conversion is 87.9% of net income. Operating cash flow was -$304.9M, with capex of -$3.8M. The largest bridge item is Working Capital at -$54.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportOct 14, 2026
4Statement of changes in beneficial ownershipOct 6, 2026

Does IBRX generate free cash flow?

ImmunityBio, Inc. (IBRX) generated -$308.78M of free cash flow in fiscal 2025.

How much operating cash flow does IBRX produce?

Operating cash flow was -$304.94M, before capital expenditures of $3.85M.